| __timestamp | Dyne Therapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1145000000 | 176081000 |
| Thursday, January 1, 2015 | 2028000000 | 157939000 |
| Friday, January 1, 2016 | 2281000000 | 164073000 |
| Sunday, January 1, 2017 | 2932000000 | 169243000 |
| Monday, January 1, 2018 | 24000 | 168489000 |
| Tuesday, January 1, 2019 | 271000 | 172526000 |
| Wednesday, January 1, 2020 | 700000 | 200649000 |
| Friday, January 1, 2021 | 1088000 | 237513000 |
| Saturday, January 1, 2022 | 3345000 | 353358000 |
| Sunday, January 1, 2023 | 2461000 | 586886000 |
Unleashing insights
In the dynamic world of biotechnology and pharmaceuticals, understanding cost structures is crucial. Lantheus Holdings, Inc. and Dyne Therapeutics, Inc. offer a fascinating comparison in their cost of revenue over the past decade. From 2014 to 2023, Lantheus Holdings has shown a steady increase, with costs rising from approximately $176 million to nearly $587 million, marking a growth of over 230%. This reflects their expanding operations and market reach.
Conversely, Dyne Therapeutics presents a more volatile picture. Their cost of revenue peaked dramatically in 2017, reaching over $2.9 billion, before plummeting to just $2.5 million by 2023. This sharp decline suggests significant strategic shifts or operational changes. The contrasting trends between these two companies highlight the diverse challenges and strategies within the industry, offering valuable insights for investors and analysts alike.
Novo Nordisk A/S vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
AstraZeneca PLC vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amgen Inc. and Dyne Therapeutics, Inc.
United Therapeutics Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Lantheus Holdings, Inc. vs MorphoSys AG
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Lantheus Holdings, Inc. vs Taro Pharmaceutical Industries Ltd.
Lantheus Holdings, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Xenon Pharmaceuticals Inc. vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down MorphoSys AG and Dyne Therapeutics, Inc.'s Expenses
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Dyne Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Galapagos NV vs Dyne Therapeutics, Inc.